Dip.to di Clinica Medica, Nefrologia e Scienze della Prevenzione, Università degli Studi di Parma, Parma, Italy.
Vascul Pharmacol. 2013 Jan;58(1-2):39-47. doi: 10.1016/j.vph.2012.08.005. Epub 2012 Aug 30.
Iodinated radiocontrast media (RCM) are usually well tolerated, but their large and increasing use renders their toxicity a relevant problem, especially in high risk patients. The aim of the study was to investigate the possible toxic or activating effects of iodixanol on endothelial cells (EC) and the putative in vitro protective action of N-acetylcysteine and rosuvastatin. Morphology, oxidative status, redistribution of heat-shock protein 60 and secretion of proinflammatory products were studied in cultured human EC through confocal microscopy, immunofluorescence and immuno-enzymatic methods. EC reacted to iodixanol with shrinking and bulging, increase in intracellular oxidation and translocation of Heat Shock Protein 60 to the cell membrane. The secretion of proinflammatory products was strongly stimulated by sequential incubation of EC with iodixanol and TNFα (p<0.00001 for all tested molecules, namely TNFα, IL-8, sVCAM-1, MCP-1, and IL-6). N-acetylcysteine prevented morphologic and oxidative derangements, and significantly reduced proinflammatory product secretion (P range<0.0001 to<0.00001 for TNFα, VCAM-1, MCP-1, and IL-6); rosuvastatin inhibited morphology and oxidative modifications only. Our data help clarifying the mechanisms of early and late toxicity of RCM and support the use of anti-oxidant and anti-inflammatory agents for optimization of radiological procedures in high risk patients.
碘造影剂(RCM)通常具有良好的耐受性,但由于其广泛且不断增加的应用,其毒性已成为一个相关问题,尤其是在高危患者中。本研究旨在探讨碘克沙醇对血管内皮细胞(EC)的潜在毒性或激活作用,以及 N-乙酰半胱氨酸和瑞舒伐他汀的潜在体外保护作用。通过共聚焦显微镜、免疫荧光和免疫酶学法研究了培养的人 EC 的形态、氧化状态、热休克蛋白 60 的重新分布以及促炎产物的分泌。EC 对碘克沙醇的反应为收缩和膨出、细胞内氧化增加以及热休克蛋白 60 向细胞膜易位。EC 先用碘克沙醇和 TNFα 孵育,然后促炎产物的分泌受到强烈刺激(所有测试分子,即 TNFα、IL-8、sVCAM-1、MCP-1 和 IL-6,p<0.00001)。N-乙酰半胱氨酸可预防形态和氧化紊乱,并显著减少促炎产物的分泌(TNFα、VCAM-1、MCP-1 和 IL-6 的 P 值范围为<0.0001 至<0.00001);瑞舒伐他汀仅抑制形态和氧化改变。我们的数据有助于阐明 RCM 的早期和晚期毒性机制,并支持使用抗氧化和抗炎药物来优化高危患者的放射学程序。